ADMA - ADMA Biologics Adds ASCENIV's First Sale To A Strong List Of 2019 Accomplishments

ADMA Biologics (ADMA) recently announced their first commercial sales of ASCENIV. Accordingly, the market embraced the announcement, and the share price spiked up to just under $5.00 per share. Although the first sale of a product is not a marquis catalyst for most biotech companies, ASCENIV’s first sale should be seen as a significant event for ADMA investors. Now, ADMA has three commercial products on the market which will permit the company to start taking advantage of the current IVIG shortage in the United States. If all goes well, investors should expect the company to

Read more ...